Abstracts tagged "prognostic factors"

Abstract Number: 1532 • ACR Convergence 2022
The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging
sanya Chhikara¹, Adinan Kanda², mohamed Ismail², Fredrick Ogugua², Rejowana Rouf², khaled Ismail², Parag Bawaskar², Jerry Molitor² and Chetan Shenoy², ¹University of Minnesota, New York, NY, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary…
Abstract Number: 0783 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
Md Yuzaiful Md Yusof¹, Jack Arnold², Benazir Saleem³, Claire Vandevelde³, Shouvik Dass³, Sinisa Savic¹, Edward M Vital¹ and Paul Emery¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: There are concerns regarding the safety of rituximab (RTX) during the COVID-19 pandemic due its effect on humoral immunity. Data from registries during pre-vaccination…
Abstract Number: 1680 • ACR Convergence 2022
Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis
Felice Rivellese¹, Elena Pontarini², Cankut Cubuk¹, Alessandra Nerviani¹, Liliane Fossati-Jimack¹, Anna Surace¹, Elisabetta Sciacca³, Katriona Goldmann¹, Michele Bombardieri⁴, Myles Lewis¹ and Costantino Pitzalis¹, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Queen Mary University of London, Biancavilla, Italy, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom
Background/Purpose: Despite extensive studies, the relationship between circulating and local immune cells and clinico-pathological features of Immune-Mediated Inflammatory Diseases remains unclear. Recently, synovium-specific cell states…
Abstract Number: 0244 • ACR Convergence 2022
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
Yicong Li¹, Chun Wu², Michael Maldonado², Peter Schafer², S. Louis Bridges, Jr.³, William Rigby⁴, Vivian Bykerk³, Jane Buckner⁵ and Jinqi Liu², ¹Parexel International, Durham, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Hospital for Special Surgery, New York, NY, ⁴Dartmouth Hitchcock Medical Center, Lebanon, PA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular…
Abstract Number: 0918 • ACR Convergence 2022
Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study
BERNARD COMBE¹, Yoshiya Tanaka², Maya Buch³, Gerd Burmester⁴, Beatrix Bartok⁵, Alena Pechonkina⁶, Ling Han⁶, Kahaku Emoto⁷, Shungo Kano⁷, Thijs Hendrikx⁸ and Daniel Aletaha⁹, ¹Montpellier University, Montpellier, France, ²University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Gilead Sciences, Inc., La Jolla, CA, ⁶Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, K.K., Tokyo, Japan, ⁸GLPG, Leiden, Netherlands, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) and poor prognostic factors1 (PPF) are at risk for progression without adequate treatment. Filgotinib (FIL) is a once…
Abstract Number: 1737 • ACR Convergence 2022
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner¹, Ulvi Ahmadov¹, Morten Aagaard Nielsen², Lasse Sommer Kristensen¹ and Tue Kragstrup³, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some…
Abstract Number: 0260 • ACR Convergence 2022
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
You-Jung Ha¹, Seunghwan Shin², SE RIM CHOI³, Eun Ha Kang¹ and Yun Jong Lee¹, ¹Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ²Lunit Inc, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The primary target for the treatment of rheumatoid arthritis (RA) is achieving remission or low disease activity with proper use of DMARD. Besides controlling…
Abstract Number: 1024 • ACR Convergence 2022
Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
Philipp Sewerin¹, stephanie Knippschild², Sabrina Tulka², Xenofon Baraliakos³ and Ralph Brinks², ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Chair for Medical Biometry and Epidemiology, Witten, Germany, ³Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 0532 • ACR Convergence 2021
Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
Alejandro Durán-Sotuela¹, Mercedes Fernández-Moreno¹, Maria Vázquez-Mosquera¹, Paula Ramos-Louro¹, Andrea Dalmao-Fernández¹, Sara Relaño¹, Victoria Suárez-Ulloa², Vanesa Balboa-Barreiro³, Natividad Oreiro¹, Jorge Vázquez-García¹, Francisco Blanco-García⁴ and Ignacio Rego-Pérez¹, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²Plataforma de Bioinformática. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006, A Coruña, Spain, ³Unidad de apoyo a la Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁴Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: There is a pressing need of identifying patients suffering the rapid progressive phenotype of Osteoarthritis (RPOA) to implement prevention strategies and to include them…
Abstract Number: 0702 • ACR Convergence 2021
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
Sarvar Nazir¹, Lisa Rider², Ira Targoff³, Stanley Naides⁴, Andrew Mammen⁵, Steven Greenberg⁶ and Adam Schiffenbauer⁵, ¹NIEHS, NIH, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Self, Dana Point, CA, ⁵National Institutes of Health, Bethesda, MD, ⁶Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
Abstract Number: 0707 • ACR Convergence 2021
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
Kazuki Hirano¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Yuji Hosono¹, Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…
Abstract Number: 0965 • ACR Convergence 2021
Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup
Benjamin Naovarat¹, Francis Williams², Gloria Salazar³ and John Reveille⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²Specialists for Health/Wellmed, Shavano Park, TX, ³University of Texas Medical School at Houston/McGovern Medical School, Houston, TX, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There are concerns about using immunosuppressive agents for treatment of rheumatic diseases in patients with HIV infection due to concerns of opportunistic infection. We…
Abstract Number: 1228 • ACR Convergence 2021
Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting
Rieke Alten¹, Christiane Rauch², Bettina Bannert³, Sara Marsal⁴, Maya Buch⁵, Roberto Caporali⁶, Melanie Chartier⁷, Sean Connolly⁸, Hedley Griffiths⁹, Xavier Mariette¹⁰, Michael Nurmohamed¹¹, Yusuf Patel¹², Peter Peichl¹³, Raimon Sanmarti¹⁴, Yedid Elbez¹⁵ and Karissa Lozenski⁸, ¹Schlosspark-Klinik University, Berlin, Germany, ²Bristol Myers Squibb, Munich, Germany, ³Universitätsspital Basel, Basel, Switzerland, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵University of Leeds, Leeds, United Kingdom, ⁶Policlinico S. Matteo University, Pavia, Italy, ⁷Bristol Myers Squibb, Rueil-Malmaison, France, ⁸Bristol Myers Squibb, Princeton, NJ, ⁹Barwon Rheumatology Service, Geelong, Australia, ¹⁰Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ¹¹ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, ¹²Hull Royal Infirmary, Hull, United Kingdom, ¹³Evangelical Hospital, Vienna, Austria, ¹⁴Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁵Deepscover, Puteaux, France
Background/Purpose: A treat-to-target approach for RA management is recommended, with the aim of achieving remission.1,2 The Abatacept SubCutaneOus in Routine clinical practicE (ASCORE; NCT02090556) study…
Abstract Number: 1356 • ACR Convergence 2021
Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
Ashley Elliott¹, Gary Wright², Adrian Pendleton² and Madeleine Rooney¹, ¹Centre for Experimental Medicine , School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK, Belfast, Northern Ireland, United Kingdom, ²Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Enthesitis is an important aspect of disease in PsA and its clinical assessment has problems in terms of sensitivity and overlap with alternative co-morbid…

« Previous Page
1
…
8
9
10
11
12
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].